frequency of the bcr/abl rearrangements and associated alterations detected by fish during monitoring of patients taking imatinib mesylate in isolation freqüência do rearranjo bcr/abl e alterações associadas detectadas por fish no monitoramento de pacientes em uso exclusivo do mesilato de imatinibe

Clicks: 256
ID: 179871
2006
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #40 of 100 articles by views in journal of computational and graphical statistics : a joint publication of american statistical association, institute of mathematical statistics, interface foundation of north america

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The introduction of imatinib mesylate as treatment of chronic myelogenous leukemia has saved many patients, but the success of therapy is hampered by resistance and possible non-destruction of the malignant clone. This article describes the cytogenetic responses and abnormal cytogenetic patterns involving the ABL and BCR genes detected by FISH in patients who use exclusively imatinib. The results showed that other alterations involving the BCR and ABL genes do not seem to be related to resistance to the drug as they occur in low frequencies and can not be associated to the cytogenetic response or to the time of treatment. Moreover, the response to imatinib seems to be individual and unpredictable, independent of the time of treatment and of its initiation after diagnosis.
A introdução do mesilato de imatinibe como tratamento da leucemia mielóide crônica tem salvado muitos pacientes, mas o sucesso da terapia tem sido prejudicado pela resistência e possível não destruição do clone maligno. Este artigo descreve a resposta citogenética e padrões citogenéticos anormais envolvendo os genes ABL e BCR detectados por FISH em pacientes em uso exclusivo de imatinibe. Os resultados mostraram que outras alterações envolvendo os genes BCR e ABL não parecem estar relacionadas à resistência à droga, elas ocorrem em baixas freqüências e podem não estar associadas à resposta citogenética ou ao tempo de tratamento. Contudo, a resposta ao imatinibe parece ser individual e imprevisível, independente do tempo e do início do tratamento após o diagnóstico.
Reference Key
vendrame-goloni2006revistafrequency Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Cristina B. Vendrame-Goloni;Andréa B. Carvalho-Salles;Octávio Ricci Júnior;Carlos E. Miguel;Agnes C. Fett-Conte
Journal journal of computational and graphical statistics : a joint publication of american statistical association, institute of mathematical statistics, interface foundation of north america
Year 2006
DOI
10.1590/S1516-84842006000200010
URL
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842006000200010
Keywords
fish imatinib

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.